vs
INTEGRA LIFESCIENCES HOLDINGS CORP（IART）とUSA Compression Partners, LP（USAC）の財務データ比較。上の社名をクリックして会社を切り替えられます
INTEGRA LIFESCIENCES HOLDINGS CORPの直近四半期売上が大きい（$434.9M vs $252.5M、USA Compression Partners, LPの約1.7倍）。USA Compression Partners, LPの前年同期比売上増加率が高い（2.7% vs -1.7%）。USA Compression Partners, LPの直近四半期フリーキャッシュフローが多い（$87.7M vs $-5.4M）。過去8四半期でINTEGRA LIFESCIENCES HOLDINGS CORPの売上複合成長率が高い（8.6% vs 4.9%）
インテグラ・ライフサイエンス・ホールディングスは、米国ニュージャージー州プリンストンに本社を置くグローバル医療機器企業で、1989年に設立されました。皮膚再生、脳神経外科、再建外科、一般外科向けの製品を製造しており、同社の人工皮膚は重度の熱傷やその他の皮膚創傷の治療に用いられる世界初の量産可能な人工皮膚組織です。
USA Compression Partners, LPは米国に本拠を置く天然ガス圧縮サービスプロバイダーであり、石油・ガス業界の上流・中流・下流分野の顧客向けに、カスタム圧縮システム、保守サービス、運用支援を提供し、天然ガスの生産・加工・輸送の効率化を支えています。
IART vs USAC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $434.9M | $252.5M |
| 純利益 | — | $27.8M |
| 粗利率 | 50.8% | — |
| 営業利益率 | 5.3% | 30.3% |
| 純利益率 | — | 11.0% |
| 売上前年比 | -1.7% | 2.7% |
| 純利益前年比 | — | 9.1% |
| EPS（希薄化後） | $-0.03 | — |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $434.9M | $252.5M | ||
| Q3 25 | $402.1M | $250.3M | ||
| Q2 25 | $415.6M | $250.1M | ||
| Q1 25 | $382.7M | $245.2M | ||
| Q4 24 | $442.6M | $245.9M | ||
| Q3 24 | $380.8M | $240.0M | ||
| Q2 24 | $418.2M | $235.3M | ||
| Q1 24 | $368.9M | $229.3M |
| Q4 25 | — | $27.8M | ||
| Q3 25 | $-5.4M | $34.5M | ||
| Q2 25 | $-484.1M | $28.6M | ||
| Q1 25 | $-25.3M | $20.5M | ||
| Q4 24 | — | $25.4M | ||
| Q3 24 | $-10.7M | $19.3M | ||
| Q2 24 | $-12.4M | $31.2M | ||
| Q1 24 | $-3.3M | $23.6M |
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.5% | — | ||
| Q2 25 | 50.4% | — | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | 54.0% | — | ||
| Q1 24 | 56.1% | — |
| Q4 25 | 5.3% | 30.3% | ||
| Q3 25 | 2.9% | 33.5% | ||
| Q2 25 | -123.4% | 30.6% | ||
| Q1 25 | -4.0% | 28.3% | ||
| Q4 24 | 8.0% | 30.3% | ||
| Q3 24 | -2.1% | 31.5% | ||
| Q2 24 | -0.7% | 32.9% | ||
| Q1 24 | 1.1% | 29.2% |
| Q4 25 | — | 11.0% | ||
| Q3 25 | -1.3% | 13.8% | ||
| Q2 25 | -116.5% | 11.4% | ||
| Q1 25 | -6.6% | 8.4% | ||
| Q4 24 | — | 10.3% | ||
| Q3 24 | -2.8% | 8.1% | ||
| Q2 24 | -3.0% | 13.3% | ||
| Q1 24 | -0.9% | 10.3% |
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-6.31 | — | ||
| Q1 25 | $-0.33 | — | ||
| Q4 24 | $0.25 | — | ||
| Q3 24 | $-0.14 | — | ||
| Q2 24 | $-0.16 | — | ||
| Q1 24 | $-0.04 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $263.7M | $8.6M |
| 総負債低いほど良い | $726.6M | $2.5B |
| 株主資本純資産 | $1.0B | — |
| 総資産 | $3.6B | $2.6B |
| 負債/資本比率低いほどレバレッジが低い | 0.70× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $263.7M | $8.6M | ||
| Q3 25 | $267.9M | — | ||
| Q2 25 | $253.6M | $2.0K | ||
| Q1 25 | $273.3M | $2.0K | ||
| Q4 24 | $273.6M | $14.0K | ||
| Q3 24 | $277.6M | $79.0K | ||
| Q2 24 | $296.9M | $9.0K | ||
| Q1 24 | $663.1M | $8.0K |
| Q4 25 | $726.6M | $2.5B | ||
| Q3 25 | $736.3M | $2.5B | ||
| Q2 25 | $745.9M | $2.5B | ||
| Q1 25 | $755.6M | $2.5B | ||
| Q4 24 | $760.5M | $2.5B | ||
| Q3 24 | $765.3M | $2.5B | ||
| Q2 24 | $770.2M | $2.5B | ||
| Q1 24 | $775.0M | $2.5B |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.6B | — |
| Q4 25 | $3.6B | $2.6B | ||
| Q3 25 | $3.6B | $2.7B | ||
| Q2 25 | $3.7B | $2.7B | ||
| Q1 25 | $4.1B | $2.7B | ||
| Q4 24 | $4.0B | $2.7B | ||
| Q3 24 | $4.1B | $2.8B | ||
| Q2 24 | $4.1B | $2.8B | ||
| Q1 24 | $4.1B | $2.8B |
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.48× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $11.8M | $139.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $-5.4M | $87.7M |
| FCFマージンFCF / 売上 | -1.2% | 34.8% |
| 設備投資強度設備投資 / 売上 | 4.0% | 20.5% |
| キャッシュ転換率営業CF / 純利益 | — | 5.02× |
| 直近12ヶ月FCF直近4四半期 | $-31.1M | $277.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $11.8M | $139.5M | ||
| Q3 25 | $40.9M | $75.9M | ||
| Q2 25 | $8.9M | $124.2M | ||
| Q1 25 | $-11.3M | $54.7M | ||
| Q4 24 | $50.7M | $130.2M | ||
| Q3 24 | $22.5M | $48.5M | ||
| Q2 24 | $40.4M | $96.7M | ||
| Q1 24 | $15.8M | $65.9M |
| Q4 25 | $-5.4M | $87.7M | ||
| Q3 25 | $25.8M | $51.9M | ||
| Q2 25 | $-11.2M | $101.1M | ||
| Q1 25 | $-40.2M | $36.3M | ||
| Q4 24 | $21.1M | $101.2M | ||
| Q3 24 | $-7.2M | $19.8M | ||
| Q2 24 | $10.7M | $48.2M | ||
| Q1 24 | $291.0K | $-32.7M |
| Q4 25 | -1.2% | 34.8% | ||
| Q3 25 | 6.4% | 20.7% | ||
| Q2 25 | -2.7% | 40.4% | ||
| Q1 25 | -10.5% | 14.8% | ||
| Q4 24 | 4.8% | 41.1% | ||
| Q3 24 | -1.9% | 8.2% | ||
| Q2 24 | 2.6% | 20.5% | ||
| Q1 24 | 0.1% | -14.3% |
| Q4 25 | 4.0% | 20.5% | ||
| Q3 25 | 3.8% | 9.6% | ||
| Q2 25 | 4.8% | 9.3% | ||
| Q1 25 | 7.6% | 7.5% | ||
| Q4 24 | 6.7% | 11.8% | ||
| Q3 24 | 7.8% | 12.0% | ||
| Q2 24 | 7.1% | 20.6% | ||
| Q1 24 | 4.2% | 43.0% |
| Q4 25 | — | 5.02× | ||
| Q3 25 | — | 2.20× | ||
| Q2 25 | — | 4.35× | ||
| Q1 25 | — | 2.66× | ||
| Q4 24 | — | 5.12× | ||
| Q3 24 | — | 2.51× | ||
| Q2 24 | — | 3.10× | ||
| Q1 24 | — | 2.80× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
USAC
| Revenue From Contract Operations Excluding Revenue From Related Party | $231.7M | 92% |
| Entities Affiliated With Energy Transfer LP | $16.6M | 7% |
| Transferred At Point In Time | $5.4M | 2% |
